Letters Long acting β2 agonists in adult asthma

Use long acting β2 agonists only when asthma cannot be controlled otherwise

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f6552 (Published 06 November 2013) Cite this as: BMJ 2013;347:f6552
  1. Joerg Hasford, professor for medical biometry and epidemiology1
  1. 1IBE, Ludwig-Maximilians-Universitaet Muenchen, D-81377 Munich, Germany
  1. has{at}ibe.med.uni-muenchen.de

When reviewing the value of long acting β2 agonists in the treatment of asthma,1 Currie and colleagues did not properly report the results of one of the major studies, the Salmeterol Multi-centre Asthma Research Trial (SMART).2

When salmeterol was approved in the US in 1994, the Food and Drug Administration asked the manufacturer to run a large scale placebo controlled safety trial owing to accumulating concerns about the …

View Full Text

Sign in

Log in through your institution

Subscribe